FDA Drug recall D-0280-2023
CEFEPIME, (a) 2GM IN NS 100ML (b)8GM IN NS 400ML (c) 12GM IN NS 600ML, used with a Curlin or Home pump, Sentara Home Infusion Pharmacy Serv…
- FDA Drug
- Class II
- terminated
- Published 2023-02-22
On 2023-02-22 the FDA classified a Class II recall of CEFEPIME, (a) 2GM IN NS 100ML (b)8GM IN NS 400ML (c) 12GM IN NS 600ML, used with a Curlin or Home pump, Sentara Home Infusion Pharmacy Serv… by Sentara Infusion Services, citing lack of sterility assurance.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0280-2023 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2022-12-27 |
| Published | 2023-02-22 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Sentara Infusion Services |
| Distribution | US |
Product
CEFEPIME, (a) 2GM IN NS 100ML (b)8GM IN NS 400ML (c) 12GM IN NS 600ML, used with a Curlin or Home pump, Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320
Reason
Lack of sterility assurance
Identifiers
| code_info | Beyond Use Date December 24-31, 2022 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0280-2023%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.